Daewoong Pharma
KRX:069620

Watchlist Manager
Daewoong Pharma Logo
Daewoong Pharma
KRX:069620
Watchlist
Price: 144 300 KRW 0.28% Market Closed
Market Cap: 1.7T KRW
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
Daewoong Pharma

Wall Street analysts forecast Daewoong Pharma stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Daewoong Pharma is 203 417.14 KRW with a low forecast of 181 800 KRW and a high forecast of 231 000 KRW.

Lowest Forecast
Wall Street Target
181 800 KRW
26% Upside
Average Forecast
Wall Street Target
203 417.14 KRW
41% Upside
Highest Forecast
Wall Street Target
231 000 KRW
60% Upside
Lowest
Price Target
181 800 KRW
26% Upside
Average
Price Target
203 417.14 KRW
41% Upside
Highest
Price Target
231 000 KRW
60% Upside
Daewoong Pharma Competitors:
Price Targets
4577
Daito Pharmaceutical Co Ltd
1% Upside
ORX
Orexo AB
162% Upside
1177
Sino Biopharmaceutical Ltd
14% Upside
C
214370
Caregen Co Ltd
18% Upside
4577
Daito Pharmaceutical Co Ltd
1% Upside
ORX
Orexo AB
162% Upside
1177
Sino Biopharmaceutical Ltd
14% Upside
C
214370
Caregen Co Ltd
18% Upside
A
002821
Asymchem Laboratories Tianjin Co Ltd
2% Upside
AJANTPHARM
Ajanta Pharma Ltd
17% Upside
C
CONCORDBIO
Concord Biotech Ltd
21% Upside
326030
SK Biopharmaceuticals Co Ltd
57% Upside

Revenue
Forecast

Revenue Estimate
Daewoong Pharma

For the last 8 years the compound annual growth rate for Daewoong Pharma's revenue is 6%. The projected CAGR for the next 3 years is 6%.

6%
Past Growth
6%
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Daewoong Pharma

For the last 8 years the compound annual growth rate for Daewoong Pharma's operating income is 24%. The projected CAGR for the next 3 years is 16%.

24%
Past Growth
16%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Daewoong Pharma

For the last 8 years the compound annual growth rate for Daewoong Pharma's net income is -1%. The projected CAGR for the next 3 years is 100%.

-1%
Past Growth
100%
Estimated Growth
Estimates Accuracy
-17%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Daewoong Pharma's stock price target?
Price Target
203 417.14 KRW

According to Wall Street analysts, the average 1-year price target for Daewoong Pharma is 203 417.14 KRW with a low forecast of 181 800 KRW and a high forecast of 231 000 KRW.

What is Daewoong Pharma's Revenue forecast?
Projected CAGR
6%

For the last 8 years the compound annual growth rate for Daewoong Pharma's revenue is 6%. The projected CAGR for the next 3 years is 6%.

What is Daewoong Pharma's Operating Income forecast?
Projected CAGR
16%

For the last 8 years the compound annual growth rate for Daewoong Pharma's operating income is 24%. The projected CAGR for the next 3 years is 16%.

What is Daewoong Pharma's Net Income forecast?
Projected CAGR
100%

For the last 8 years the compound annual growth rate for Daewoong Pharma's net income is -1%. The projected CAGR for the next 3 years is 100%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 257,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.